Panacea Biotec Limited (PANACEABIO) Price & Analysis

Compare

0 Followers

PANACEABIO Stock Chart & Stats

₹358.50

-₹0.60(-0.13%)

At close: Jan 08 4:00 PM EST

₹358.50

-₹0.60(-0.13%)

Day’s Range― - ―

52-Week Range₹306.00 - ₹581.00

Previous CloseN/A

Volume134.82K

Average Volume (3M)12.44K

Market Cap

₹19.43B

Enterprise Value₹19.00B

Total Cash (Recent Filing)₹1.28B

Total Debt (Recent Filing)₹229.00M

Price to Earnings (P/E)144.8

Beta1.55

Next Earnings

May 28, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.65

Shares Outstanding61,250,744

10 Day Avg. Volume14,140

30 Day Avg. Volume12,438

Financial Highlights & Ratios

PEG Ratio-0.53

Price to Book (P/B)3.31

Price to Sales (P/S)4.94

P/FCF Ratio-35.56

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Strong Balance Sheet / Low LeveragePanacea's very low debt-to-equity (0.03) and high equity ratio provide durable financial flexibility. This reduces refinancing risk, supports capital allocation for R&D or capacity, and allows the company to withstand cyclical pharma demand shifts without immediate reliance on external debt markets.

High Gross Profit MarginA ~64% gross margin signals lasting strength in product mix and cost control, especially versus commoditized generics. Sustained high gross margins create room to fund commercial expansion, absorb pricing pressure on generics, and support investment in higher-value vaccines and biologics over the medium term.

Vertical Integration & Vaccine/Manufacturing CapabilitiesIn-house R&D, manufacturing and vaccine/biologics capabilities give structural advantages: control of supply, quality, and margins plus the ability to win institutional tenders or contract manufacturing deals. This integration supports durable revenue channels and market access.

Bears Say

Negative Operating And Free Cash FlowPersistent negative operating and free cash flow erode liquidity over time and limit internal financing for capex, working capital, and product launches. Without sustainable cash generation, the company may need external funding, diluting returns or constraining strategic investments.

Ongoing Losses / Negative EBIT And Net IncomeConsistent negative EBIT and net income indicate structural operational challenges, reducing retained earnings and limiting reinvestment capacity. Prolonged losses can weaken competitive positioning by constraining marketing, R&D and price resilience versus better-funded peers.

Declining Assets And Shareholders' EquityA trend of falling total assets and shareholders' equity suggests shrinking operating scale or impairments. This can reduce production capacity, erode collateral for borrowing, and signal underinvestment, all of which impair the company's ability to grow revenues sustainably.

Panacea Biotec Limited News

Panacea Biotec Disputes ₹9.38 Crore Tax Penalty, Sees No Material Business Impact

Panacea Biotec Limited ( ($IN:PANACEABIO) ) has provided an announcement. Panacea Biotec Limited has disclosed that it has...

3M ago

Panacea Biotec Announces Leadership Changes and Policy Updates

Panacea Biotec Limited ( ($IN:PANACEABIO) ) has shared an announcement. Panacea Biotec Limited announced key changes in its...

3M ago

Panacea Biotec Announces 41st AGM Details and Compliance Measures

Panacea Biotec Limited ( ($IN:PANACEABIO) ) has shared an update. Panacea Biotec Limited announced the publication of a...

6M ago

Panacea Biotec Releases Q1 2025 Financial Results

Panacea Biotec Limited ( ($IN:PANACEABIO) ) has shared an announcement. Panacea Biotec Limited has published its unaudited standalone...

7M ago

Panacea Biotec Announces Director Change

Panacea Biotec Limited ( ($IN:PANACEABIO) ) has shared an update. Panacea Biotec Limited announced the completion of Mr....

12M ago

Panacea Biotec Announces Senior Management Change

Panacea Biotec Limited ( ($IN:PANACEABIO) ) just unveiled an update. Panacea Biotec Limited announced the superannuation of Mr....

12M ago

PANACEABIO FAQ

What was Panacea Biotec Limited’s price range in the past 12 months?

Panacea Biotec Limited lowest stock price was ₹306.00 and its highest was ₹581.00 in the past 12 months.

What is Panacea Biotec Limited’s market cap?

Panacea Biotec Limited’s market cap is ₹19.43B.

When is Panacea Biotec Limited’s upcoming earnings report date?

Panacea Biotec Limited’s upcoming earnings report date is May 28, 2026 which is in 71 days.

How were Panacea Biotec Limited’s earnings last quarter?

Panacea Biotec Limited released its earnings results on Feb 11, 2026. The company reported ₹0.65 earnings per share for the quarter, beating the consensus estimate of N/A by ₹0.65.

Is Panacea Biotec Limited overvalued?

According to Wall Street analysts Panacea Biotec Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Panacea Biotec Limited pay dividends?

Panacea Biotec Limited pays a Annually dividend of ₹0.75 which represents an annual dividend yield of N/A. See more information on Panacea Biotec Limited dividends here

What is Panacea Biotec Limited’s EPS estimate?

Panacea Biotec Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Panacea Biotec Limited have?

Panacea Biotec Limited has 61,250,744 shares outstanding.

What happened to Panacea Biotec Limited’s price movement after its last earnings report?

Panacea Biotec Limited reported an EPS of ₹0.65 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -5.399%.

Which hedge fund is a major shareholder of Panacea Biotec Limited?

Currently, no hedge funds are holding shares in IN:PANACEABIO

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Panacea Biotec Limited

Panacea Biotec Limited, a biotechnology company, engages in the research and development, manufacture, and marketing of pharmaceuticals, vaccines, and biosimilars in India. It operates through Vaccines and Formulations segments. The company's product portfolio includes prescription products in various therapeutic areas, such as pain management, diabetes and cardiovascular management, oncology, renal disease management, osteoporosis management, anti-tubercular, and gastro-intestinal care; and vaccines for anthrax, dengue, Japanese encephalitis, and others. It also exports its products to over 30 countries worldwide, including the United States, Germany, the Russian Federation, Sri Lanka, the Philippines, etc. The company has a collaboration agreement with the Russian Direct Investment Fund for producing Covid-19 vaccine Sputnik-V; and the Coalition for Epidemic Preparedness Innovations and Translational Health Science and Technology Institute to develop vaccine candidates that could protect against SARS-Cov-2 variants and other Beta coronaviruses. Panacea Biotec Limited was incorporated in 1984 and is based in New Delhi, India.